Myomo, Inc. Issues November 2017 Shareholder Letter
November 07 2017 - 8:00AM
Business Wire
Provides an Update on Third Quarter 2017 and
Ongoing Commercial Activities
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a
commercial stage medical robotics company, today issued a letter to
shareholders to give an update on third quarter 2017 and ongoing
MyoPro® commercial activities.
An accompanying digital shareholder letter can be viewed at:
shareholderletters.myomo.com/q3-17.
Dear Fellow Shareholders:
Welcome to the first edition of our Investor Relations digital
shareholder letter, whose purpose is to keep you informed about
Myomo's progress. Since completing our IPO in June, we have been
implementing various sales and marketing programs to grow the
company. We established additional MyoPro Centers of Excellence to
distribute our products to patients around the country; increased
our Marketing presence online and begun our international
expansion. We are leveraging our FDA registered, CE Marked, and
only commercial, proprietary technology to restore function to the
millions of patients with upper limb paralysis.
We believe we have the strategic focus, business model, and an
expanding operational footprint to ably serve this market,
facilitating our growth.
Thank you for your investment in MYO shares, which provides us
the resources to grow the business and create shareholder value
over time.
Sincerely;
Paul R. GudonisChairman & Chief Executive Officer
About MyomoMyomo, Inc. is a commercial stage medical
robotics company that offers expanded mobility for those suffering
from neurological disorders and upper limb paralysis. Myomo
develops and markets the MyoPro product line. MyoPro is a powered
upper limb orthosis designed to restore function to the weakened or
paralyzed arms of patients suffering from CVA stroke, brachial
plexus injury, traumatic brain or spinal cord injury, ALS or other
neuromuscular disease or injury. It is currently the only marketed
device that, sensing a patient’s own EMG signals through
non-invasive sensors on the arm, can restore an individual’s
ability to perform activities of daily living, including feeding
themselves, carrying objects and doing household tasks. Many are
able to return to work, live independently and reduce their cost of
care. Myomo is headquartered in Cambridge, Massachusetts, with
sales and clinical professionals across the U.S. For more
information, please visit www.myomo.com.
Forward Looking StatementsThis press release contains
forward-looking statements regarding the Company's future business
expectations, including the launch of MyoPro for Veterans, which
are subject to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
only predictions and may differ materially from actual results due
to a variety of factors. Our actual results could differ materially
from those anticipated in these forward looking statements for many
reasons, including, without limitation, risks related to regulatory
approval and market acceptance of our products, and the other risk
factors contained in our filings made with the Securities and
Exchange Commission. More information about factors that
potentially could affect Myomo's financial results is included in
Myomo's filings with the Securities and Exchange Commission. The
Company cautions readers not to place undue reliance on any such
forward-looking statements, which speak only as of the date made.
The Company disclaims any obligation subsequently to revise any
forward-looking statements to reflect events or circumstances after
the date of such statements or to reflect the occurrence of
anticipated or unanticipated events.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171107005913/en/
For Myomo:ir@myomo.comorInvestor Relations:PCG
AdvisoryVivian Cervantes,
212-554-5482vivian@pcgadvisory.comorPublic
Relations:GreenoughRachel Robbins,
617-275-6521rrobbins@greenough.biz
Myomo (AMEX:MYO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myomo (AMEX:MYO)
Historical Stock Chart
From Apr 2023 to Apr 2024